Search Results for “ breast cancer ” – Page 23 – media

Natural products and herbal medicines show promise in fight against COVID-19

Researchers in China and the United States have called for more research into the potential prophylactic effects of natural products and herbal medicines on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent coronavirus disease 2019 (COVID-19). In an article recently published in the journal Frontiers in Pharmacology, the team discussed natural products that have exhibited an inhibitory effect on SARS-CoV-2 and herbal medicines that have been tested as potential therapies for COVID-19. “In this review, we aimed to provide a new perspective regarding COVID-19 prevention,” writes Jia-xu Chen from Jinan University in Guangzhou, and colleagues from the University of Houston, and the University of California. The researchers suggest that while the world awaits effective treatments and a commercially available vaccine, the repurposing of natural products and herbal medicines as prophylactics represents a promising approach to at least slow the transmission of SARS-CoV-2. “In the interest of public health, this ...
- Source: drugdu
- 1,340
- November 18, 2020
Covid-19
Contraceptive Vaginal Ring; Annovera granted FDA Approval

Annovera (segesterone acetate and ethinyl estradiol vaginal system), a multi-use donut-shaped ring, was recently approved and presented to the Population Council by the FDA.
- Source: MDEdge
- 1,027
- August 13, 2018
contraception FDA New Approvals
FDA Warns of Unapproved Vaginal ‘Rejuvenation’ Procedures

The US-FDA has warned against medical device manufacturers for developing cosmetic vaginal rejuvenation procedures to treat vaginal atrophy, laxity, itching/dryness, pain during sex or urination and reduced sexual sensation.
- Source: Medpagetoday
- 856
- August 1, 2018
FDA Policies
PharmaAsia Recap

Recent news regarding pharma companies in Asia
- Source: FiercePharma
- 733
- July 3, 2018
Asia Market Views pharmaceutical company
Novartis Prepare Case for Earlier Kisqali Use

On Sunday, at the American Society of Clinical Oncology’s annual meeting, Novartis revealed the final outcome, showing that among patients with HR-positive, HER2-negative breast cancer, adding Kisqali to fulvestrant kept the disease away for eight months longer than fulvestrant alone.
- Source: Ddu
- 613
- June 4, 2018
cancer Company Insight Novartis
Indian Medical Devices Market – An Overview

The IVD sector in the country is chiefly characterized by 70 percent laboratories offering pathology services and 30 percent entities doling out radiology and imaging services. Though domestic players are flexing their muscles and are gearing to provide new-age diagnostic services with path-breaking innovations and strategic investments, multinational companies continue to hold sway over 60% of the domestic IVD market which is expected to grow by leaps and bounds in coming times.
- Source: Ddu
- 1,074
- May 28, 2018
India Market Views medical device products
NICE sticks with ‘no’ for earlier use of Halaven

Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s Halaven should not be funded by the NHS as a second-line of attack against a certain form of breast cancer.
- Source: pharmatimes
- 1,831
- February 23, 2018
breast cancer Market Views NHS
Why AstraZeneca’s New Drug Strategy Seems to be Bearing Fruit

Pharma giant AstraZeneca has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reutersreported Thursday.
- Source: china-pharmacy
- 489
- February 7, 2018
AstraZeneca New Drug Strategy
AstraZeneca’s PARP Inhibitor Lynparza Gets Approval in Japan

AstraZeneca AZN and partner Merck MRK announced that the Japanese Ministry of Health, Labour and Welfare has granted approval to its PARP inhibitor, Lynparza, as a maintenance therapy for relapsed ovarian cancer, irrespective of BRCA mutation status in patients who have responded to their last platinum-based chemotherapy.
- Source: finance.yahoo
- 678
- January 26, 2018
cancer inhibitor New Approvals ovarian
Pfizer, Arvinas Forge $830M Protein Degradation R&D Deal

Two months after expanding a licensing deal with Genentech, privately-held Arvinas LLC struck another lucrative deal with a major pharmaceutical company. Connecticut-based Arvinas inked a deal with Pfizer worth up to $830 million to develop small molecules that can degrade proteins.
- Source: Biospace
- 526
- January 8, 2018
Genentech Pfizer pharmaceutical company PROTAC small molecule therapeutics

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.